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OBJECTIVES: The objective of the analysis was to compare trends of single versus 
multiple technology appraisals (STA versus MTA) recommendations for new tech-
nologies conducted by NICE. Analysis was also conducted for products with European 
Union (EU) orphan designation. Further analysis was conducted to identify any dis-
ease areas that could be particularly challenging for companies planning a European 
launch of any new products, aiming to support planning for sequencing across the 
EU. METHODS: A longitudinal database containing all technology appraisal guidance 
published by NICE since the formation of the organization was analyzed. Analysis 
of products by disease area was conducted by classification into British National 
Formulary (BNF) categories. All published guidance was included thus reviews 
of technology appraisals, which overwrite earlier guidance, were not accounted 
for. RESULTS: In 2000-2007, the ratio of guidance published for MTAs to STAs was 
3:1 (54 versus 17). However, this ratio was reversed in 2008-2014, when guidance was 
published for 46 MTAs and 132 STAs. In 2009, 92% of STA guidance included positive 
or restricted recommendation (n= 12), decreasing to a historical low of 52% in 2013 
(n= 27) and increasing to 85% in 2014 (n= 20). 50% of recommendations for orphan 
products were positive or restricted in 2011 and 2013 (n= 6) but 100% were positive 
or restricted in 2012 and 2014 (n= 3). The overall recommendation rate is lower for 
orphan products than no-orphan products (67% versus 73%). Malignant disease and 
immunosuppression treatments were the most common STAs but had the second 
lowest recommendation rate (59%, n= 71). Cardiovascular treatments were most con-
sistently recommended (100%, n= 19). CONCLUSIONS: A decreasing proportion of 
appraisals include multiple technologies. There have been substantial variations in 
annual recommendations from STAs, possibly due to the choice of appraisal commit-
tee and evidence review group, which makes it very challenging for manufacturers 
to predict likely outcomes.
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OBJECTIVES: Data published by the Office for Health Economics in 2011 showed 
rejection from the SMC was more likely for orphan than for non-orphan prod-
ucts. Following a review of the SMC in 2012, the process for appraising end-of-life, 
orphan and ultra-orphan drugs was modified to facilitate greater access for patients 
in Scotland. We analyze if the revised SMC process has been successful in provid-
ing more positive recommendations for orphan products and which factors may 
influence the decision. METHODS: Analyses were based on a validated, longitudi-
nal database of all recommendations from 2002 to 2014. Products with a European 
Orphan designation were analysed. SMC recommendations following full submission, 
resubmission or abbreviated submission were reviewed and sub divided into British 
National Formulary (BNF) category. RESULTS: In 2002-2014, there were 8 abbreviated 
submissions to the SMC for orphan products, 68 full submissions and 25 resubmis-
sions. The positive recommendations rate (with or without restriction) from 2002-2013 
was 53% (n= 92); in 2014 this recommendation rate increased to 89% (n= 9). Up to 2013, 
malignant disease and immunosuppressive treatments accounted for 43% of the 
published guidance of orphan products with a recommendation rate of 50% (n= 40); 
in 2014 this improved to 80% (n= 5). Cardiovascular treatments have a high recom-
mendation rate of 92% (n= 13) but treatments for musculoskeletal and joint diseases 
have the lowest success with all three submissions receiving negative recommenda-
tion. In 2013, evidence for 7 orphan products was not submitted to the SMC within 
the required 3 months of license thus received automatic negative recommenda-
tion, however, this reduced to only one non-submission in 2014. CONCLUSIONS: The 
SMC recommendation rate for orphan products, particularly malignant disease and 
immunosuppressive drugs, has improved from 2013 to 2014 suggesting the revised 
SMC appraisal process may be more effective in enabling the SMC to provide positive 
recommendations for orphan products.
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OBJECTIVES: Since formation in 2002, the Scottish Medicines Consortium (SMC) has 
evaluated 608 health technology assessment (HTA) submissions of new medicines for 
use in Scotland. They have, therefore, reviewed more clinical and cost-effectiveness 
evidence for medicines than any other HTA organization in the world. Trends in 
SMC guidance were analysed to provide insights on likely recommendations of new 
products as manufacturers navigate the UK market. METHODS: All analyses were 
based on a validated, longitudinal database of all published guidance from 2002 to 
2014. SMC recommendations following full submission, resubmissions or abbreviated 
submissions were reviewed and then subdivided into British National Formulary (BNF) 
category. RESULTS: From 2002 to 2014, the SMC has published guidance following 608 
full submissions, 232 abbreviated submissions, 157 non-submissions, 158 resubmis-
sions and 5 Independent review panels. The proportion of products not recommended 
has fallen from 40% in 2007 (n= 98) to only 17% in 2014 (n= 84). Products falling into the 
malignant disease and immunosuppression BNF category were the most common 
submission to the SMC (20% of submissions, n= 197) with an approval rate steadily 
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OBJECTIVES: To describe reporting rates of gender-specific safety outcomes 
for new molecular entity (NME) drugs approved from the US Food and Drug 
Administration (US FDA) between 2009 and 2013 METHODS: New drug applica-
tion (NDA) files for all NME drugs that were approved for systemic use in men and 
women were surveyed from the US FDA database. Specific reviews and key word 
searches were made for descriptions or tabulation of gender-specific inferential 
statistics on the drug safety section. The rates of inclusion of explicit descriptions 
or reports of statistical significance were calculated. RESULTS: Of all 457 approved 
drugs during the study period, 118 NMEs were included for the evaluation. Of 
those, 8 NMEs and 13 NMEs were excluded due to gender specific indications or 
non-systemic route of administration, respectively, thereby remaining 97 NME 
drugs were further reviewed. On average, gender-specific safety outcome descrip-
tions were included in 74.2% (72/97) of the reviews. Gender-specific statistical 
significance was reported in 13% of the reviews. Format of the outcome descrip-
tions was inconsistent varying from statement in the body text to table without 
descriptions. CONCLUSIONS: About one in four NDA reviews for NMEs was lacking 
sufficient descriptions on gender-specific safety outcomes and the format of the 
safety outcome reports by gender was inconsistent.
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OBJECTIVES: Little guidance exists for healthcare professionals on how to evaluate 
and use CER studies with new unfamiliar designs or methods. To fill this gap, the 
CER Collaborative (AMCP, IPSOR, and NPC) developed task force reports and on-line 
tools. The aim of this study was to determine if a multi-media continuing educa-
tion (CE) program, largely derived from task-force reports and related online CER 
Collaborative tools, improved learner ability and confidence to assess CER studies 
for use in real-world decision-making. METHODS: Twenty healthcare profession-
als registered for a 19-hour, ACPE-approved CER Certificate Program (CCP) which 
included five self-paced, online modules and case studies: prospective and retro-
spective observational studies, indirect treatment comparisons, models, and syn-
thesizing information from studies with various designs. A final live workshop was 
conducted to enhance learner skills through case presentation and peer critique. 
After CCP completion, learners assessed their ability to evaluate CER studies using a 
Likert scale (1= strongly disagree, 5= strongly agree). RESULTS: In the first cohort of 
learners, 18 (90%) completed the program on schedule. Significant improvement in 
self-reported ability to evaluate CER study design on their relevance and credibility 
ranged from 29.17% (CI 18.50 - 39.83) to 61.76% (CI 49.08 – 74.45) at program comple-
tion. Learners indicated high confidence in their CER evidence assessment abilities 
(mean score 4.17; CI 3.93 – 4.40). CONCLUSIONS: As new or unfamiliar CER study 
designs and analyses become available, there will be an increasing need for clini-
cians and other decision-makers to understanding how to assess the relevance and 
credibility of CER studies to inform decision-making. The CER Certificate Program, 
was associated with improved healthcare decision-makers’ self-reported ability to 
evaluate CER and apply it for use in decision-making.
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OBJECTIVES: A review of the literature was conducted to determine whether there 
is an appropriate definition for market access. The original perception was that 
it relates to securing market authorization, as well as enabling prescribing of the 
product. A working definition for pharmaceutical market access was proposed as 
“a process of enabling patient access to pharmaceutical products, not only through 
gaining regulatory approval, but also through gaining an acceptable optimal price 
and reimbursement status to manufacturers and payers.” The objective of this 
survey was to determine how appropriate the proposed definition is by compar-
ing it to definitions proposed by differing professionals within the healthcare 
industry. METHODS: A review of the literature was undertaken, followed by the 
development of a questionnaire aimed at eliciting the various determinants of 
pharmaceutical market access, both from the patient and payer perspectives. This 
survey was administered to professionals in three settings involving ISPOR European 
Congress, EMAUD educational course, and a pharmaceutical company, with forty 
eight, forty five, and seventeen respondents, respectively. The respondents were 
categorized as belonging to: academia, pharmaceutical industry, healthcare pro-
fession, policy maker/Health Technology Assessment Agency (payer), and consul-
tancy. Responses were recorded verbatim, and then coded by the interviewers to 
aid analysis. RESULTS: The survey suggested there is an inadequate understanding 
of market access, and this is independent of the professional background of the 
respondent. Furthermore, there is not a consistent agreement as to what factors 
influence the successful development and commercialization of pharmaceutical 
products. CONCLUSIONS: Successful market access of pharmaceutical products 
requires a wider understanding of the role of patients and payers in the develop-
ment and commercialization by all stakeholders in the healthcare delivery system. 
Further research is needed into this field as it has important health policy implica-
tions for patient care.
